NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED UROTHELIAL CANCER OF THE UPPER URINARY-TRACT

被引：60

作者：

IGAWA, M

URAKAMI, S

SHIINA, H

KISHI, H

HIMENO, Y

ISHIBE, T

USUI, T

机构：

[1] Department of Urology, Shimane Medical University, Izumo

[2] Department of Urology, Hiroshima University School of Medicine, Hiroshima

来源：

UROLOGIA INTERNATIONALIS | 1995年 / 55卷 / 02期

关键词：

NEOADJUVANT CHEMOTHERAPY; UROTHELIAL CANCER; LOCALLY ADVANCED; UPPER URINARY TRACT;

D O I：

10.1159/000282755

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Cisplatin-based multiple-drug chemotherapy is currently considered the most effective treatment for advanced and metastatic urothelial cancers. We treated 15 patients with Locally advanced urothelial cancers of the upper urinary tract using the cisplatin-based multiple-drug regimen in a neoadjuvant setting. The regimens administered were: M.-VAC (methotrexate, vinblastine, doxorubicin and cisplatin); MEC (methotrexate, etoposide and cisplatin), or M-VEC (methotrexate, vinblastine, epirubicin and cisplatin). Total nephroureterectomy was performed in all patients and response was evaluated pathologically. Of 15 patients 2 (13%) achieved a pathological complete response, 6 (40%) a pathological partial response, for an overall response rate of 53% (95% confidence limits 29-77%). The median durations of response were 54 months for patients with a pathological complete response and 15.5 months for patients with a pathological partial response. One of six patients with a pathological partial response and 4 of 7 with no remission died of cancer. While a positive relationship between the pathological response and prognosis was observed, adequate follow-up is needed to assess the ability of neoadjuvant chemotherapy to improve the prognosis of patients with locally advanced urothelial cancer of the upper urinary tract.

引用

页码：74 / 77

页数：4

共 17 条

[1]

Crawford E.D., Natale R.B., Burton H., Southwest Oncology Group Study 8710: Trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intcrgroup Trial 0080), Neoadjuvant Chemotherapy in Invasive Bladder Cancer, pp. 111-113, (1990)

[2]

Scher H.I., Yagoda A., Herr H.W., Sternberg C.N., Bosl G., Morse M.J., Sogani P.C., Watson R.C., Dershaw D.D., Reuter V., Geller N., Hollander P.S., Vaughan E.D., Whitmore W.F., Fair W.R., Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion, J Urol, 139, pp. 470-474, (1988)

[3]

Frciha F., Dc Vries C., Torti F., Neoadjuvant and adjuvant chemotherapy of transitional cell carcinoma of the urothelium with cisplatin, methotrexate and vinblastine, World J Urol, 6, pp. 153-157, (1988)

[4]

Cummings K.B., Nephrectomy: Rationale in the management of transitional cell carcinoma of the upper urinary tract, Urol Clin North Am, 7, pp. 569-578, (1980)

[5]

WHO, Handbook for Reporting Results of Cancer Treatment, (1979)

[6]

Harmcr M.H., TNM Classification of Malignant Tumours, (1978)

[7]

Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Herr H.W., Morse M.J., Sogani P.C., Vaughan E.D., Bander N., Weiselbcrg L.R., Geller N., Hollander P.S., Lipperman R., Fair W.R., Whitmore W.F., M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium, J Urol, 139, pp. 461-469, (1988)

[8]

Ruther U., Rupp W., Bauerle K., Luthgens M., Rasswciler J., Bub P., Eisenberger F., Jipp P., Methotrexate, vinblastine, 4'-epirubicin and cisplatin in advanced urothelial tract tumors: Efficacy and toxicity, World J Urol, 8, pp. 51-54, (1990)

[9]

lgawa M., Kadena H., Tacho T., Nakamoto T., Usui T., Preliminary results of methotrexate, ctoposide and cisplatin in the treatment of urothelial cancer, Urol Int, 54, pp. 80-84, (1995)

[10]

Splinter T.A.W., Pavone-Macaluso M., Jacqmin D., Roberts J.T., Carpentier P., de Pauw M., Sylvester R., A European Organization for Research and Treatment of Cancer - Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: Evaluation of clinical response, J Urol, 148, pp. 1793-1796, (1992)

← 1 2 →